Pharmaceutical

LifeSci Consulting Expands with Global Operations Consulting Capability and London Office

NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- LifeSci Consulting, a boutique strategy consulting and advisory firm focused solely on…

11 months ago

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

11 months ago

Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August

FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused…

11 months ago

Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead

First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against…

11 months ago

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan…

11 months ago

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

Recursion's Pipeline Recursion's internal pipeline as of Q2 2023Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein…

11 months ago

CorMedix Inc. Reports Second Quarter and Six Month 2023 Financial Results and Provides Business Update

Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc.…

11 months ago

Abeona Therapeutics Reports Second Quarter 2023 Financial Results

On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering…

11 months ago

XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy

Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and…

11 months ago

Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results

– In July, FDA approved YCANTH™ for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6…

11 months ago